UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): January 15, 2025

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands
 
001-42253
 
 N/A
(State or other jurisdiction
 
(Commission File Number)
 
(I.R.S. Employer
of incorporation)
 
 
Identification No.)

 

12 Abba Hillel Road

Ramat-Gan, Israel
 
5250606
(Address of principal executive offices)
 
(Zip Code)

+972-8-6286005
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which
registered
Ordinary Shares, par value $0.0009 per share
 
 SLXN
 
The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $103.50 per share
 
SLXNW
 
The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 7.01          Regulation FD Disclosure.
 
On January 15, 2025, Silexion Therapeutics Corp presented publicly an updated corporate presentation. A copy of the presentation is furnished with this Current Report on Form 8-K (this “Form 8-K”) as Exhibit 99.1 and is incorporated herein by reference.
 
The information in this Item 7.01, including the information in the corporate presentation that is being furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the corporate presentation, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.
 
Item 9.01          Financial Statements and Exhibits 
 
(d) Exhibits
     

     
104
  
Cover Page Interactive Data File (formatted in Inline XBRL)


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
SILEXION THERAPEUTICS CORP
 
 
Date: January 15, 2025
/s/ Ilan Hadar
 
Name:
Ilan Hadar
 
Title:
Chief Executive Officer
 
Exhibit 99.1

 Silencing Oncogenes at the Level of Gene Expression  Nasdaq: SLXN  Corporate Presentation January 2025 
 
 The statements contained in this presentation that are not purely historical are forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this presentation may include, for example, statements about:   the future performance of the Company, including Silexion’s projected timeline for regulatory approvals of its product candidates; and  the Company’s future plans and opportunities.  The forward-looking statements contained in this presentation are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the items in the following list:  Silexion is a development-stage company and has a limited operating history on which to assess its business;  Silexion has never generated any revenue from product sales and may never be profitable;  The approach Silexion is taking to discover and develop novel RNAi therapeutics is unproven for oncology and may never lead to marketable products;  Silexion does not have experience producing its product candidates at commercial levels, currently has no marketing and sales organization, has an uncertain market receptiveness to its product candidates, and is uncertain as to whether there will be insurance coverage and reimbursement for its potential products;  Silexion may be unable to attract, develop and/or retain its key personnel or additional employees required for its development and future success;  Additional factors relating to the business, operations and financial performance of Silexion.  Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.  2   Forward-Looking Statement  
 
 Company Overview  Silexion’s siRNA platform technology is designed to silence oncogenes and prevent the production of the mutated KRAS proteins that drive cancer growth.   Inhibition of mutations important for pancreatic, colorectal and lung cancers  Phase 2 in Locally Advanced Pancreatic Cancer (LAPC) with first-generation siG12D-Loder siRNA with extended-release delivery showed trends for Overall Survival benefit (9.3 months) and Objective Response Rate in patients harboring KRASG12D/V mutations with Loder + chemo vs. chemo alone  Second generation, SIL204, siRNA optimized and administered with Integrated Treatment Regimen to enter Phase 2/3 trial  Listed on Nasdaq on August 2024 (“SLXN”)  Late-Stage Ready Asset with Regulatory Path Forward  Clinical-stage company developing proprietary treatments for KRAS-driven cancers  KRAS-Focused RNA Interference Platform with Targeted Delivery   Promising Clinical Data in Locally Advanced Pancreatic Cancer  Compelling investment proposition 
 
 KRAS Oncogene is a Validated Target for Numerous Cancers   4   Prevalence of The Most Common Types of KRAS Mutations Across Cancers  CRC=colorectal cancer; LAPC=locally advanced pancreatic cancer; NSCLC=non-small cell lung cancer.  Lee, J.K. et al. NPJ Precis Oncol. 2022;6(1):91.  PDAC  CRC  Non-sq NSCLC  Small Bowel Adenocarcinoma  Appendix  KRAS is the most common oncogenic gene driver in human cancers with gastrointestinal cancers having high percentages of KRAS G12D/V mutations  % KRAS mutations  92%  49%  35%  53%  61% 
 
 Pancreatic Cancer Has One of the Highest Mortality Rates of All Major Cancers  BRPC=borderline resectable pancreatic cancer; LAPC = locally advanced pancreatic cancer.   1. Bray F, et al. CA Cancer J Clin. 2024;74(3):229-263. 2. Hirshberg Foundation for Pancreatic Cancer Research. Pancreatic cancer Facts. https://pancreatic.org/pancreatic-cancer/pancreatic-cancer-facts. 3. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. https://seer.cancer.gov/statfacts/html/pancreas.html. 4. Gemenetzis G, et al. Ann Surg. 2019;270(2):340-347. 5. Kleeff J, et al. Nat Rev Dis Primers. 2016;2:16022.   Local  Metastatic  At diagnosis:  10-20% resectable  30-40% LAPC + BRPC  50-60% metastatic or systemic  Types and Prevalence of Pancreatic Cancer4,5  5   There are no effective treatment options for our intended indication LAPC   3rd leading cause today in the U.S.2  2nd leading cause by 20302  12.8% 5-year relative survival (2014-2020) is one of the poorest in the U.S.3  Median overall survival for non-resectable PC populations is 14-17 months4 
 
 Innovatively Treating the Cancer-Driving KRAS at the Source and Site of Action  Moving closer to treating the mechanism of the cancer more efficiently and with a greater chance to overcome treatment-resistance  Cell proliferation  Migration  Transformation   Survival  Silexion siRNA  Intratumor delivery  KRAS small molecule inhibitors (Systemic delivery)  Functional mutated KRAS protein   Mutated KRAS mRNA  Cancer   Progression  Mutated   KRAS gene  Inhibits oncogenic protein after its functioning  Transcription  Translation  mRNA destroyed, no oncogenic KRAS mutant protein is made 
 
 Silexion Innovative Oncological Approach May Lead to Significant Improvement in Clinical Outcomes Over KRAS Inhibitors   Treatment resistance  Low tolerability with adverse events such as rashes and GI side effects that require special monitoring   Limited overall response rate and progression-free survival  Limitation of currently approved and investigational small molecule KRAS inhibitors:  Inhibit oncogenic KRAS synthesis before it is active   Integrated treatment regimen to more effectively treat both the primary tumor and micrometastases  Optimized siRNA to enhanced stability and broader activity while maintaining good safety  Silexion’s Approach 
 
 SIL204 is the Most Advanced siRNA for LAPC With a Significant Market Opportunity  KRAS mutations are present in ~92% pancreatic cancer cases1  LAPC = localized advanced pancreatic cancer; ROW=rest of the world.  *Number of KRAS G12D/V mutated LAPC were calculated based on KRAS mutations being present in 92% of pancreatic cancer patients, 70-75% with KRAS G12D and G12V mutations and 30-35% of cases being LAPC. Potential for cancers wirh pan KRAS G12x activity  1. Lee, J.K. et al. NPJ Precis Oncol. 2022;6(1):91. 2. Yousef, A. et al. NPJ Precis Oncol. 20024;8(1):27. 3. Global Cancer Observatory. Pancreatic Cancer. 2022. https://gco.iarc.who.int/media/globocan/factsheets/cancers/13-pancreas-fact-sheet.pdf. 4. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. 2023. https://seer.cancer.gov/statfacts/html/pancreas.html.   SIL204 covers > 74% of KRAS mutations in PDAC2 while currently available KRAS G12C treatment are treating ~1.5%  Total Addressable Market in LAPC  U.S.  E.U.  Annual PC cases  66,4004  146,4773  KRAS-G12D/V mutated LAPC incidence*  ~16,000  ~35,000  8   U.S. ~$2B  E.U ~$3B 
 
 LODER  Phase 2 Trial Data 
 
 Phase 2 Trial of Loder Completed in 2023 – a Proof-of-Concept  Two-part, open label, study of LODER + SoC chemotherapy vs SoC chemotherapy alone across the U.S. and Israel in patients with non-resectable pancreatic cancer  SoC=standard of care.  Arm 1: LODER + SOC Chemo (n=18)  Day 0 Randomization  Long-term follow up   Screening  Death  Determination of eligibility  First LODER administration  ~7 days later 1st chemo  Week 8 – 1st CT  Arm 2: SOC Chemo (n=11)  Every 12 weeks – LODER administration   Every 12 weeks – CT  Screening  Death  Determination of eligibility  First LODER administration  ~7 days later 1st chemo  Week 8 – 1st CT  Arm 2: LODER + SOC Chemo (n=20)  Every 12 weeks – LODER administration   Every 12 weeks – CT  Long-term follow up   Cohort 1 (randomized)  Cohort 2 (single arm)  Key inclusion criteria  Non-resectable without signs of metastasis  ECOG Status ≤ 1  Both cohorts all patients meeting inclusion/exclusion criteria randomized without checking for KRAS mutation status  Endpoints  Overall survival (OS)   Response rate (RR, RECIST v1.1)   Safety  Tolerability  10  
 
 Baseline Characteristics and Cohorts Information  Due to results of a clinical trial indicating FOLFIRINOX’s advantage over GnP as SoC chemotherapy, cohort 2’s SoC chemotherapy was changed from GnP (used in cohort 1) to FOLFIRINOX.   BRPC=borderline resectable pancreatic cancer; GnP=gemcitabine/nab-paclitaxel; LAPC=locally advanced pancreatic cancer; SoC=standard-of-care.  *KRAS mutations were determined in 31 patients in total. In cohort 1, 12 patients in the treatment arm and 10 patients in the control arm were tested; in cohort 1, 9 patients were tested.  Cohort 1  (n=29)  Cohort 2  (n=20)  Design/Arms  Randomized, controlled (SoC)  Single arm  Population  Locally advanced PC (LAPC)  Non-resectable (BRPC+ LAPC)   Nationality   62% U.S. ( 4 sites) , 38% Israel (5 sites)  Male/ Female %  42% male; 58% female  Median age (years)  69.7   64.9  KRAS Mutations  G12D/V*: Loder 11/12, Control 5/10  G12R*: Loder: 1/12, Control 5/10  G12D/V*: Loder 7/9  G12R*: Loder: 2/9  Avg Loder cycles  2.8  2.1  Total number of Loder injections  370  SoC chemotherapy  gemcitabine/nab-paclitaxel (GnP)   (modified) FOLFIRINOX ((m)FFX)   11  
 
 Loder Treatment Led to Robust Objective Response Rate in Patients with LAPC Harboring G12D/V Mutations*  LAPC=locally advanced pancreatic cancer.  *Overall response rate was confirmed by RECIST 1.1 of the target tumor, as analyzed by sites.  Bar curves below the solid black line starting at y-axis -0.3 indicates criteria for positive RECIST response.  Chemo:  Loder:  R = Non-resectable tumor becomes resectable  G12D  G12V  Cohort 1  Cohort 1+2  Best % change in tumor size from baseline  Cohort 1  LODER+Chemo  Cohort 1+2  LODER+Chemo  Chemo   % Response  55 (6/11)  56 (10/18)  20 (1/5)   % Response+ becoming resectable   64  67  40 
 
 Cohort 1 Patients Treated with Loder Had 9.3 Months Improvement in Overall Survival  13   * SoC (Control) OS consistent with recent trials for LAPC (Gemenetzis G, et al. Ann Surg. 2019;270(2):340-347).  Hazard ratio (HR)=0.59, (95% CI, 0.18, 1.96, p=0.39)  Time to death is slower, 41% reduction in the rate of mortality.  Patients living longer with Loder+SOC vs. SOC  Days  Overall Survival in Cohort 1  SOC chemo median =13.4 mo.*  siRNA+SOC chemo median=22.7 mo. 
 
 Phase 2 Safety Results  Serious Adverse Events (SAEs) Related to Treatment in Patients with LAPC who Received LODER + Chemotherapy (treatment plus EUS-endoscopy administration procedure)     LODER + SOC chemo (n=38)  SAE  All grades  n (%)  Grades 3-4  n (%)  Gastrointestinal disorders  3 (8%)  2 (5%)  Hematemesis  1 (3%)  0 (0%)   STOMACH ACUTE PAIN  1 (3%)  1 (3%)  Gastric hemorrhage  1 (3%)  1 (3%)  General disorders and administration site conditions  2 (5%)  0 (0%)    Fever  2 (5%)   0 (0%)   Hepatobiliary disorders  3 (8%)  2 (5%)  Cholangitis  2 (5%)  1 (3%)  Obstructive Hyperbilirubinemia  1 (3%)  1 (3%)  Infections and infestations  2 (5%)  2 (5%)  Sepsis  1 (3%)  1 (3%)  Pancreas infection   1 (3%)  1 (3%)  Depression  1 (3%)  1 (3%)  Injury, poisoning and procedural complications  1 (3%)  1 (3%)  procedural hemorrhage  1 (3%)  1 (3%)  Nervous system disorders  1 (3%)  1 (3%)  Presyncope   1 (3%)  1 (3%)  14  
 
 Loder Was Overall Well Tolerated  The Phase 2 PoC clinical trial investigators reported that Loder treatment was well tolerated; Safety events were primarily related to procedure  Intratumor administration of extended-release siRNA via endoscopy (EUS) is safe  No Treatment Emergent Adverse Events (TEAEs) leading to study discontinuation related to Loder treatment   No meaningful observations in any vital sign parameter nor any physical examination findings in the study   Independent Drug Safety Monitoring Board (DSMB) Reviews had no safety concerns nor safety restrictions  In a subset analysis, no measurable amount of Loder was detected (<BLQ) in any plasma samples suggesting low systemic levels  15  
 
 Building upon the Loder results, we optimized:  siRNA:  Integrated Treatment Regimen for primary tumor and micrometastases  Enhanced stability  Broadening activity  
 
 SIL204  KRAS G12D/V siRNA with  potential for pan-KRASG12x activity  
 
 Leveraging Loder Clinical Data to Further Improve SIL204 Potential Efficacy and Safety  18   HR=Hazard Ratio.  *EUS endoscopy is a standard procedure used to obtain ultrasound guided biopsies once every 3 months.  `  LODER  SIL204  siRNA target  KRAS G12D/V+ KRAS amplify  KRAS G12D/V+ KRAS amplify, potential pan KRASG12x  Stability in human serum (HS) and rat pharmacokinetics  HS <1 hr  HS > 48 hrs, Remains at substantial levels for >56 Days in plasma and tissues after single subcutaneous administration to rats  Access to tumor cell site of action  No hydrophobic lead  Added hydrophobic lead to increase siRNA access into cell  Route and Ease of administration  EUS-endoscopy* with larger needle; Required loading device  S.C. administration and EUS Endoscopy* with smaller and more flexible needle; No loading device needed  Improvement in OS with chemo vs. chemo alone  + 9.3 monthsHR=0.59 Reduction in rate of death by 41% compared to chemotherapy alone  TBD in Phase 2/3 trial with expected improvement in OS  Safety  Generally well tolerated; Safety events were primarily related to procedure  Expectations for good safety profile 
 
 SIL204 is Stable In Vitro for Over 48 Hours in Human Serum  19   siRNA strand placed in human serum and tested for stability  Stability of siRNA Strand in Human Serum   Potentially longer effectiveness of siRNA  Greater ability to diffuse throughout the fibrous tumor environment  Potential in other indications  Previous studies have shown siG12D (Loder) half-life to be 5 min in human serum. 
 
 SIL204 Remains at Substantial Levels for >56 Days in Plasma and Tissues   Single subcutaneous administration SIL204 solution (10mg, not formulated) to Sprague Dawley rats  20   Potential for longer effectiveness of siRNA for treating micrometastases with dosing on monthly basis 
 
 SIL204 Shows Broad Inhibition Across Human KRAS Mutations at Sub-Nanomolar Concentrations  SIL204 maintains and expands the silencing activity of the Loder  21   Model is a co-transfection setup in mouse Hepa1-6 cells with Dual-Glo reporter plasmids.  Mutation  NegativesiRNAControl  WT   KRAS  KRAS   G12D  KRAS   G12V  KRAS   G12C  KRAS   G12R  KRAS   Q61H*  KRAS  G13D*  IC50 (nM)  0.16  0.19  0.44  0.47  0.59  0.24  0.37  MAX Inhibition (%)  0-7  91  90  80  73  71  88  88  IC50=half-maximal inhibitory concentration.   *G13D and Q61H tested in separate studies from the G12 mutations and wild type (non-mutated).  
 
 SIL204 Robustly Inhibits Growth of Human Pancreatic Tumor Cell Line (Panc-1) in Dose-Dependent Manner  22   UT=untreated. 
 
 SIL204-MP Inhibited Human Pancreatic Cancer Xenograft Growth in Mice  SIL2-04-MP = microparticle formulated SIL204.  SIL204 significantly reduced tumor area and increased tumor necrosis  ~Day -7: Panc-1(G12D mutation) cells were xenografted to mice (s.c.) and grown to ~200mm3   Day 1: SIL204-MPs or PBS (phosphate buffer Saline) was injected sub-cutaneous into animals  Day 30: Tumors were dissected, and histological slices from the center of the tumor taken and analyzed for necrosis  23   After 4 weeks 50% of Panc-1 tumors showed complete necrosis  1 7 14 21 28 
 
 SIL204 Inhibited Human Pancreatic Cancer Xenograft Growth in Mice  *p<0.05 ; ***p<0.0005  S.C. = sub cutaneous.  SIL204 significantly reduced tumor volume and growth while increasing the necrosis (cell death) within the tumor   Day 1: Capan-1 (G12V) luciferase cells were xenografted to mice (s.c.) concurrently with SIL204 formulated in extended-release microparticles  Days 3-15: mice were evaluated for bioluminescence to evaluate relative tumor cell counts  Day 15: tumors were removed, area determined and analyzed by histology for % necrosis from tumor center slice  24   % Necrosis  5.5  4.5  3.5  2.5  1.5  0.5  Bioluminescence (106)  Tumor area (mm2)  *  *** 
 
 SIL204 Development Strategy in LAPC   2023  2024  H1 2025  H2 2025  H1 2026  H2 2026  Clinical proof of concept for Loder in LAPC in an approvable endpoint for FDA  Optimization of siRNA on various fronts; selection of SIL204  Received guidance on trial design from the German Federal Institute for Drugs and Medical Devices (BfArM), intratumor administration  Initiate toxicology studies SIL204  GMP production API (SIL204)  Submit CTA in E.U. for Phase 2/3  Initiate Phase 2/3, LAPC Germany/Israel  Leverage safety clinical data from first trial segment Phase 2/3   Pre-IND meeting FDA  Submit IND to FDA  Expand Phase 2/3 to USAadditional EU, etc   25   Indicates completed activity. Unmarked activities to be performed.  Meeting with German authorities for regulatory buy-in/scientific advice (BfArM) on integrated regimen, and plans to proceed to Phase 2/3 trial  GMP production injectable formulation 
 
 Program  Indication   Setting  Discovery  Preclinical  Phase 1  Phase 2  Phase 3  Status/ Anticipated Milestone  LODER  siG12D + KRAS amplify with extended release PLGA delivery system  Locally advanced pancreatic cancer  Adjunct to chemotherapy  Phase 2 completed: observed 9.3 months improvement with LODER over SOC.  Continue development of SIL204.  SIL204 (Integrated treatment regimen)  KRAS G12D/V (primary), pan-KRAS (secondary)   Locally advanced pancreatic cancer  Adjunct to chemotherapy  H1 2026: CTA submission in E.U. for Phase 2/31H 2026: Initiate Phase 2/3  Colorectal cancer  Adjunct to chemotherapy  H2 2025: Preclinical  Focused Pipeline to Address KRAS-driven Solid Tumor Localized Cancers  26   CTA=clinical trial application; SOC=standard of care.  Phase 2 Completed   Current Focus: Optimized siRNA formulation with Integrated Treatment Regimen  
 
 Strong Intellectual Property Protection  * Exclusivity can be extended under country-specific regulatory-based extension rules.  10 patents issued worldwide | 6 patents pending worldwide  IP Portfolio  Technology  Term  Compositions for inhibition of KRAS expression and treatment regimens therewith  2045*(provision patent)  Inhibition of KRAS expression and methods of use thereof  2043* (International patent application)  siRNA against KRAS G12x for regional perineural invasion or pain associated with a solid tumor  Pending US/EU, expected term till 2040  Nanoparticles  2016-2032 (E.U.)  G12D siRNA Sequences  2014-2032 (U.S.)  Loder  2015-2030 (U.S.)  2014-2029 (E.U.) 
 
 World-Renowned Expert Scientific Advisory Board  Eileen M. O'Reilly, MD  Memorial Sloan Kettering, NY, NY  Winthrop Rockefeller Endowed Chair of Medical Oncology; Co-Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research; Section Head, Hepatopancreatobi  Hana Algul, MD  Technical University of Munich, Germany  chair for tumor metabolism; Director of the Comprehensive Cancer Center Munich, Germany at the Klinikum rechts der Isar, and Mildred-Scheel-professor and   Milind Javle, MD  The University of Texas & MD Anderson Cancer Center, Houston, TX  Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine  Philip A. Philip, MD   Henry Ford Health, Detroit, MI  Director, Gastrointestinal Oncology; Co-Director, Pancreatic Cancer Center; Medical Director, Research and Clinical Care Integration, Henry Ford Cancer Institute  Talia Golan, MD  Sheba Tel Hashomer Hospital,, Israel  Head, Sheba Pancreatic Cancer Center - SPCC  Matthew Katz, MD  The University of Texas & MD Anderson Cancer Center, Houston, TX  Department Chair, Department of Surgical Oncology, Division of Surgery and Professor.  Andrew M. Lowy, MD  UC San Diego, San Diego, CA  Chief, Division of Surgical Oncology; Professor of Surgery  Mark A. Schattner, MD  Memorial Sloan Kettering, NY, NY  Chief, Gastroenterology, Hepatology and Nutrition Service  28   Thomas Seufferlein, MD  University Hospital Ulm, German  Director of Internal Medicine University Hospital Ulm, President German Cancer Society 
 
 Highly Experienced Leadership Team  Ilan Hadar, MBA Chairman and Chief Executive Officer  > 25 years of multinational managerial and corporate experience with pharmaceutical and high-tech companies  Mitchell Shirvan, PhD, MBA Chief Scientific and Development Officer  > 25 years of experience in R&D, innovation and discovery in biotech companies  Mirit Horenshtein Hadar, CPA Chief Financial Officer  > 15 years of corporate finance experience in senior financial positions of public companies and privately held companies, in the pharmaceutical and high-tech industries  Ilan Levin, Director   Former Chairman & Chief Executive Officer of Moringa Acquisition Corp with 25 years of experience as an executive and venture capital/private equity investor in high-tech, Israel-related ventures  29  
 
 Investment Highlights  CTA=clinical trial application; IND=investigational new drug.   Clinical-stage company with proprietary oncogene siRNA platform  Integrated Treatment Regimen (To more effectively treat both the primary tumor and micrometastases  Phase 2 clinical trial with first generation Loder in LAPC showed 9.3 months improvement in FDA approvable endpoint of overall survival  Lead Candidate SIL204 with enhanced siRNA stability and broader activity  Advanced RNA therapeutic candidate in oncology  Late-Stage Ready Asset with Regulatory Path Forward  Strong Partnerships with Solid IP Portfolio   Guidance received from German Federal Institute for Drugs and Medical Devices (BfArM) on Phase 2/3 trial  Submit CTA in E.U. in 1H 2026 and initiate Phase 2/3 trial of SIL204 in 1H 2026   Plan for U.S. IND submission with clinical safety data from limited number of patients the trial in E.U.  Established partnerships for GMP production of siRNA and formulations  PCT submitted with favorable international review for claims for siRNA composition of matter and use, IP exclusivity through December 2043 plus extension  
 
 Thank You  Nasdaq: SLXN  Ilan Hadar   Chairman & Chief Executive Officer  email: ihadar@silexion.com  Dr. Mitchell Shirvan  Chief Scientific and Development Officer  email: mshirvan@silexion.com  Mirit Horenshtein Hadar, CPA  Chief Financial Officer  email: mirit@silexion.com 
 

v3.24.4
Document and Entity Information
Jan. 15, 2025
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 15, 2025
Entity File Number 001-42253
Entity Registrant Name Silexion Therapeutics Corp
Entity Central Index Key 0002022416
Entity Incorporation, State or Country Code E9
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One 12 Abba Hillel Road
Entity Address, City or Town Ramat-Gan
Entity Address, Country IL
Entity Address, Postal Zip Code 5250606
City Area Code 972
Local Phone Number 8-6286005
Entity Emerging Growth Company true
Entity Ex Transition Period false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Ordinary Shares, par value $0.0001 per share [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Ordinary Shares, par value $0.0009 per share
Trading Symbol SLXN
Security Exchange Name NASDAQ
Warrants exercisable for Ordinary Shares at an exercise price of $11.50 per share [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Warrants exercisable for Ordinary Shares at an exercise price of $103.50 per share
Trading Symbol SLXNW
Security Exchange Name NASDAQ
Grafico Azioni Silexion Therapeutics (NASDAQ:SLXNW)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di Silexion Therapeutics
Grafico Azioni Silexion Therapeutics (NASDAQ:SLXNW)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di Silexion Therapeutics